J Korean Neuropsychiatr Assoc.  2012 May;51(3):134-138. 10.4306/jknpa.2012.51.3.134.

High-Dose Zolpidem Dependence and Detoxification from Withdrawal Symptoms Using Diazepam

• Rhee SJ
• Ko SM
• Choi JW
• Park H

• KMID: 2194610
• DOI: http://doi.org/10.4306/jknpa.2012.51.3.134

Abstract

Zolpidem is a nonbenzodiazepine hypnotic for the treatment of insomnia, and known as a relatively-safe medication. However, there have been several case reports of zolpidem abuse aand dependence these days. Even though some withdrawal symptoms like seizures can occur, there has not been any standard detoxification method until now. A high dose of zolpidem has similar pharmacological properties as the rest of the benzodiazepines, even though the usual dose of zolpidem has a selectivity to the type 1 benzodiazepine receptors. We report a rare case of high-dose addiction and successful detoxification by cross-titration with diazepam.

Keyword

Addiction; Dependence; Detoxification; Diazepam; Withdrawal; Zolpidem

MeSH Terms

Benzodiazepines
Diazepam
Pyridines
Receptors, GABA-A
Seizures
Sleep Initiation and Maintenance Disorders
Substance Withdrawal Syndrome
Benzodiazepines
Diazepam
Pyridines
Receptors, GABA-A

Reference

1. American Psychiatric Association. Task Force on D-I. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. 2000. Washington, DC: American Psychiatric Publishing, Inc..

2. Joseph TD, Robert LT, Gray CY, Gary RM, Barbara GW, Posey LM. Pharmacotherapy: A Pathophysiologic Approach. 2008. 7th ed. New York: Mc Graw Hill Medical;1083–1098.

3. Doble A. New insights into the mechanism of action of hypnotics. J Psychopharmacol. 1999. 13:S11–S20.

4. Follesa P, Mancuso L, Biggio F, Cagetti E, Franco M, Trapani G, et al. Changes in GABA(A) receptor gene expression induced by withdrawal of, but not by long-term exposure to, zaleplon or zolpidem. Neuropharmacology. 2002. 42:191–198.

5. Hwang TJ, Ni HC, Chen HC, Lin YT, Liao SC. Risk predictors for hypnosedative-related complex sleep behaviors: a retrospective, cross-sectional pilot study. J Clin Psychiatry. 2010. 71:1331–1335.

6. Liappas IA, Malitas PN, Dimopoulos NP, Gitsa OE, Liappas AI, Nikolaou ChK, et al. Zolpidem dependence case series: possible neurobiological mechanisms and clinical management. J Psychopharmacol. 2003. 17:131–135.

7. Tripodianakis J, Potagas C, Papageorgiou P, Lazaridou M, Matikas N. Zolpidem-related epileptic seizures: a case report. J Psychopharmacol. 2003. 18:140–141.

8. Alexander B, Perry PJ. Detoxification from benzodiazepines: schedules and strategies. J Subst Abuse Treat. 1991. 8:9–17.

9. Ashton H. The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry. 2005. 18:249–255.

10. Wagner J, Wagner ML, Hening WA. Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother. 1998. 32:680–691.

11. Rush CR. Behavioral pharmacology of zolpidem relative to benzodiazepines: a review. Pharmacol Biochem Behav. 1998. 61:253–269.

12. Darcourt G, Pringuey D, Salliere D, Lavoisy J. The safety and tolerability of zolpidem--an update. J Psychopharmacol. 1999. 13:81–93.

13. Lobo BL, Greene WL. Zolpidem: distinct from triazolam? Ann Pharmacother. 1997. 31:625–632.

14. Sellers EM, Ciraulo DA, DuPont RL, Griffiths RR, Kosten TR, Romach MK, et al. Alprazolam and benzodiazepine dependence. J Clin Psychiatry. 1993. 54 Suppl:64–75. discussion 76-77.

15. Curtis JL, Jermaine DM. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: A pathophysiologic approach. 2002. New York: McGraw-Hill;1323–1334.

16. Hajak G, Bandelow B. Safety and tolerance of zolpidem in the treatment of disturbed sleep: a post-marketing surveillance of 16944 cases. Int Clin Psychopharmacol. 1998. 13:157–167.

17. Hajak G, Müller WE, Wittchen HU, Pittrow D, Kirch W. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction. 2003. 98:1371–1378.

18. Aragona M. Abuse, dependence, and epileptic seizures after zolpidem withdrawal: review and case report. Clin Neuropharmacol. 2000. 23:281–283.

19. Gilbert DL, Staats PS. Seizure after withdrawal from supratherapeutic doses of zolpidem tartrate, a selective omega I benzodiazepine receptor agonist. J Pain Symptom Manage. 1997. 14:118–120.

20. Sethi PK, Khandelwal DC. Zolpidem at supratherapeutic doses can cause drug abuse, dependence and withdrawal seizure. J Assoc Physicians India. 2005. 53:139–140.

21. Harrison M, Busto U, Naranjo CA, Kaplan HL, Sellers EM. Diazepam tapering in detoxification for high-dose benzodiazepine abuse. Clin Pharmacol Ther. 1984. 36:527–533.

22. Barrero-Hernandez FJ, Ruiz-Veguilla M, Lopez-Lopez MI, Casado-Torres A. [Epileptic seizures as a sign of abstinence from chronic consumption of zolpidem]. Rev Neurol. 2002. 34:253–256.

23. Suh JH, Roh HK, Eo EK, Cheon YJ, Jung KY. Clinical characteristics of acute zolpidem intoxication. J Korean Soc Clin Toxicol. 2008. 6:91–98.

24. Chen SC, Chen HC, Liao SC, Tseng MC, Lee MB. Detoxification of high-dose zolpidem using cross-titration with an adequate equivalent dose of diazepam. Gen Hosp Psychiatry. 2012. 34:210.e5–210.e7.

25. Madrak LN, Rosenberg M. Zolpidem abuse. Am J Psychiatry. 2001. 158:1330–1331.

26. Svitek J, Heberlein A, Bleich S, Wiltfang J, Kornhuber J, Hillemacher T. Extensive craving in high dose zolpidem dependency. Prog Neuropsychopharmacol Biol Psychiatry. 2008. 32:591–592.

27. Chu BC, Lai TJ, Chang CM. Seizures after supratherapeutic doses of zolpidem withdrawal: a case report. Taiwanese Psychiatry Taiwanese Psychiatry. 2008. 22:148–152.

28. Rappa LR, Larose-Pierre M, Payne DR, Eraikhuemen NE, Lanes DM, Kearson ML. Detoxification from high-dose zolpidem using diazepam. Ann Pharmacother. 2004. 38:590–594.

29. Jana AK, Arora M, Khess CR, Praharaj SK. A case of zolpidem dependence successfully detoxified with clonazepam. Am J Addict. 2008. 17:343–344.